The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines

Tirzepatide once weekly has induced a weight loss of about 20% in obese people without diabetes.

• GLP-1-based therapies have significantly impacted the treatment of overweight and obesity.
• Liraglutide 3.0 mg daily leads to a weight loss of 6-8%, while Semaglutide 2.4 mg weekly improves this to about 12-15%.
• Various GLP-1-based treatments have shown beneficial effects on body weight and liver disease.
• Ongoing developments include a combination of semaglutide and cagrilintide, as well as oral forms of semaglutide.
• Gastrointestinal adverse events are common with GLP-1 therapies, including nausea and diarrhea, but may be reduced with slow dose increases.

AI simplified